Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease

Uskudar University50 enrolled

Overview

Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.

The study is designed as a single-center, prospective clinical trial. Participants will be selected from among patients who present to the clinic and are diagnosed with stable stage Peyronie's disease. All participants who meet the eligibility criteria and provide written consent will undergo a standard Extracorporeal Shockwave Therapy protocol. All participants will be evaluated before and after treatment using the International Erectile Function Index-5 and the Quality of Life Questionnaire short form. The results will be statistically analyzed and interpreted.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Peyronie Disease

Interventions

Extracorporeal Shockwave TherapyOTHER

Extracorporeal Shockwave Therapy will follow a standard protocol. The treatment is planned as a total of 8 sessions (3000 pulses per session, 2.5 bar pressure, 15 Hz frequency) twice a week using a radial shockwave device. Focusing will be done on the penile shaft via gel according to the plaque localization, and shock waves will be applied to the plaque area.

controlOTHER

patients receiving normal routine pharmacological treatment without any special intervention

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male individuals aged 18-65 years. * Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months. * Presence of palpable penile plaque. Exclusion Criteria: * Acute inflammatory stage (painful, progressive) * Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease. * Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy. * History of penile cancer. * Severe erectile dysfunction. * Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.

Locations (1)

Koreya Serq Tebabeti

Baku, Azerbaijan

RECRUITING

Outcomes

Primary Outcomes

Erectile function

The International Index of Erectile Function is recorded as a total score. It is measured by a self-reported questionnaire with 5 domains, with each domain consisting of 5 options. The score ranges from 5 to 25, with 5 being the lowest score (severe erectile dysfunction) and 25 being the best score (maximal erection)

Time frame: 5 weeks

Short Form-36

Short Form-36 Health Survey is a non-disease-specific instrument consisting of 36 items used to assess health-related quality of life. It includes eight subscales covering physical and mental health domains. Each subscale is scored from 0 to 100, with higher scores indicating better health status, while one item assessing health change is not included in subscale scoring. A high score indicates a higher quality of life.

Time frame: 5 weeks

Central Contacts

Ömer ŞEVGİN

CONTACT

+905069787535 omer.sevgin@uskudar.edu.tr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.